Efficacy and Safety of SID142 in Patients With Peripheral Arterial Disease: A Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group, Phase III Clinical Trial

Author:

Kook HyungdonORCID,Yu Cheol WoongORCID,Choi Donghoon,Ahn Tae Hoon,Chang Kiyuk,Cho Jin-Man,Kim Soo-Joong,Park Chang GyuORCID,Cho Deok-Kyu,Kim Sang-Hyun,Lee Han CheolORCID,Jin Han-YoungORCID,Chae In-Ho,Kwon Kihwan,Ahn Sung GyunORCID,Kim Ju Han,Lee Sang-Rok,Kim Jeong-SuORCID,Kim Seok Yeon,Lim Sang WookORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference22 articles.

1. Epidemiology, classification, and modifiable risk factors of peripheral arterial disease;Shammas;Vasc Health Risk Manag,2007

2. Ethnic-specific prevalence of peripheral arterial disease in the United States;Allison;Am J Prev Med,2007

3. Epidemiology of peripheral artery disease and polyvascular disease;Aday;Circ Res,2021

4. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines;Gerhard-Herman;Circulation,2017

5. Potentiation of anti-platelet aggregating activity of cilostazol with vascular endothelial cells;Igawa;Thromb Res,1990

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3